Company intelligence / Profile preview
Dermama Biotechnology
Laweyan, Central Java, Indonesiadermama.co.id ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Dermama Biotechnology is advancing exosome-based and stem cell therapies for chronic and age-related diseases, with one of its exosome therapy candidates (EXOMSC-COV19) in advanced clinical trials for regenerative applications, including wound healing and tissue regeneration. They have a decade-long track record and collaborations with industry and academia[1][3][6][8].
- Therapeutic areas
- EndocrinologyRheumatologyOphthalmologyGastroenterologyDermatologyOtherNeurology
- Modalities
- Exosome-based therapyStem cell therapyCell therapyNanoparticle
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaborations with top research institutions and industry leaders (not specified)[1]
Beyond the preview
Go deeper on Dermama Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dermama Biotechnology.